{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:24:59Z","timestamp":1791397499149,"version":"4.3.3"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"am","delay-in-days":306,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","award":["1402-10522"],"award-info":[{"award-number":["1402-10522"]}],"id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["ZIA-AR-041153"],"award-info":[{"award-number":["ZIA-AR-041153"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.semarthrit.2025.152831","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T17:55:47Z","timestamp":1758131747000},"page":"152831","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Discontinuation versus continuation of maintenance treatment with tumor necrosis factor inhibitors in patients with rheumatoid arthritis with low disease activity or remission: A randomized double-blind placebo-controlled trial"],"prefix":"10.1016","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1857-9367","authenticated-orcid":false,"given":"Michael M.","family":"Ward","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7248-6623","authenticated-orcid":false,"given":"Arthur","family":"Weinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paloma","family":"Alejandro-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan K.","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rukmini","family":"Konatalapalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4930-3235","authenticated-orcid":false,"given":"Gail S.","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal","family":"Mikdashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Kempf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal R.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stamatina","family":"Danielides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Ghafouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3100-607X","authenticated-orcid":false,"given":"Thomas P.","family":"Olenginski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2597-1981","authenticated-orcid":false,"given":"Alice","family":"Fike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denitza","family":"Balyozova-Dinkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0471-9349","authenticated-orcid":false,"given":"Ralf","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8382-2207","authenticated-orcid":false,"given":"Lawrence","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4482-3338","authenticated-orcid":false,"given":"Subrata","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3978-6226","authenticated-orcid":false,"given":"Florina","family":"Constantinescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2025.152831_bib0001","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.semarthrit.2025.152831_bib0002","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152831_bib0003","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/acr.22646","article-title":"Epidemiology and treatment of new-onset and established rheumatoid arthritis in an insured US population","volume":"67","author":"Crane","year":"2015","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2025.152831_bib0004","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s13075-021-02599-4","article-title":"Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry","volume":"23","author":"Mease","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2025.152831_bib0005","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1136\/annrheumdis-2017-212423","article-title":"Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis","volume":"77","author":"Henaux","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152831_bib0006","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.berh.2015.09.006","article-title":"De-intensifying treatment in established rheumatoid arthritis (RA): why, how, when and in whom can DMARDs be tapered?","volume":"29","author":"Fautrel","year":"2015","journal-title":"Best Pr Res Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152831_bib0007","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1136\/annrheumdis-2016-209201","article-title":"Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions","volume":"75","author":"Schett","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152831_bib0008","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s13075-023-03199-0","article-title":"Prevalence and predictors of sustained remission\/low disease activity after discontinuation of induction or maintenance treatment with tumor necrosis factor inhibitors in rheumatoid arthritis: a systematic and scoping review","volume":"25","author":"Ward","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2025.152831_bib0009","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000133","article-title":"A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission","volume":"2","author":"Chatzidionysiou","year":"2016","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2025.152831_bib0010","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1002\/art.39626","article-title":"Stopping tumor necrosis factor inhibitor treatment in patients with established rheumatoid arthritis in remission or with stable low disease activity: a pragmatic multicenter, open-label randomized controlled trial","volume":"68","author":"Ghiti Moghadam","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152831_bib0011","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/annrheumdis-2014-205726","article-title":"Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis","volume":"75","author":"van Vollenhoven","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152831_bib0012","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1136\/annrheumdis-2020-217246","article-title":"Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study","volume":"79","author":"Emery","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152831_bib0013","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/art.41589","article-title":"Etanercept or methotrexate withdrawal in rheumatoid arthritis patients in sustained remission","volume":"73","author":"Curtis","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152831_bib0014","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2025.152831_bib0015","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.21235","article-title":"Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states","volume":"52","author":"Aletaha","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2025.152831_bib0016","first-page":"261","article-title":"How to read radiographs according to the Sharp\/van der Heijde method","volume":"27","author":"van der Heijde","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152831_bib0017","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/acr.21869","article-title":"Ultrasound joint inflammation in rheumatoid arthritis in clinical remission: how many and which joints should be assessed?","volume":"65","author":"Naredo","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2025.152831_bib0018","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1136\/annrheumdis-2012-202281","article-title":"Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study","volume":"72","author":"van der Maas","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152831_bib0019","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/sim.2244","article-title":"Choosing the analysis population in non-inferiority studies: per protocol or intent-to-treat","volume":"25","author":"Matilde Sanchez","year":"2006","journal-title":"Stat Med"},{"key":"10.1016\/j.semarthrit.2025.152831_bib0020","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/art.10190","article-title":"Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp\/van der Heijde and Larsen\/Scott scoring methods by clinical experts and comparison with the smallest detectable difference","volume":"46","author":"Bruynesteyn","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2025.152831_bib0021","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/art.42347","article-title":"American College of Rheumatology\/EULAR remission criteria for rheumatoid arthritis: 2022 revision","volume":"75","author":"Studenic","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152831_bib0022","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s41927-019-0071-x","article-title":"Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment","volume":"3","author":"Ghiti Moghadam","year":"2019","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152831_bib0023","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cyto.2016.08.014","article-title":"Molecular mechanisms of action of anti-TNF-\u03b1 agents\u2013Comparison among therapeutic TNF-\u03b1 antagonists","volume":"101","author":"Mitoma","year":"2018","journal-title":"Cytokine"},{"key":"10.1016\/j.semarthrit.2025.152831_bib0024","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000564","article-title":"Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study","volume":"4","author":"Jansen","year":"2018","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2025.152831_bib0025","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/rheumatology\/kez488","article-title":"Is radiographic progression a downside of stopping TNF-inhibitor in RA patients with low disease activity, if this is followed by flare? A sub-study of the POET-US trial","volume":"59","author":"Lamers-Karnebeek","year":"2020","journal-title":"Rheumatology"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225002021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225002021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T13:51:30Z","timestamp":1765979490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017225002021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":25,"alternative-id":["S0049017225002021"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152831","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discontinuation versus continuation of maintenance treatment with tumor necrosis factor inhibitors in patients with rheumatoid arthritis with low disease activity or remission: A randomized double-blind placebo-controlled trial","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152831","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152831"}}